Micro-CT and the histomorphometric techniques we developed are comparable and can both be used to identify incorporation of a Stentrode implanted in cerebral vessels.

Long story short, neural interfaces implanted throughout the body have demonstrated great success in treating a growing variety of conditions. Despite these successes, the longevity of implanted neural interface systems are impeded by mechanical, technological, and biological barriers. Mechanical and electronic failures can occur in any of the components of the implanted system. The immune response to an implanted neural interface consists of acute and chronic phases and differs between the central and peripheral nervous systems. Advances in material science and engineering are actively working to reduce the tissue response to implanted neural interfaces by reducing their size and stiffness as well as by using factors to reduce inflammation.

High-fidelity intracranial electrode arrays for recording and stimulating brain activity have facilitated major advances in the treatment of neurological conditions over the past decade. Traditional arrays require direct implantation into the brain via open craniotomy, which can lead to inflammatory tissue responses, necessitating development of minimally invasive approaches that avoid brain trauma. Here we demonstrate the feasibility of chronically recording brain activity from within a vein using a passive stent-electrode recording array (stentrode).

The impact of placing electrodes within a blood vessel and adjacent to the blood vessel wall was most obvious when looking at the phase responses at frequencies below 10 kHz. Conclusion: Our results show that intravascular electrodes, like those in subdural and epidural positions, show electrical properties that are suitable for recording. These results provide support for the use of intravascular arrays in clinically relevant neural prostheses and diagnostic devices. Significance: Comparison of electrochemical impedance of the epidural, intravascular, and subdural electrode array showed that all three locations are possible placement options, since impedances are in comparable ranges.

This work demonstrated that EIS could be used to determine the viability of electrode implanted chronically within a blood vessel. Impedance measurements alone were not observed to be a useful predictor of alterations occurring at the electrode tissue interface. However, measurement of 100 Hz phase angles was in good agreement with the capacitive changes predicted by the ECM and consistent with suggestions that this represents protein absorption on the electrode surface. 100 Hz phase angles stabilized after 8 days, consistent with histologically assessed samples.

In conclusion, our 3D brain slice injury model was successful as a tool for testing a biomaterial implantation therapy, highlighting the use of complex organotypic models for biomaterial testing, to close the gap between simple in vitro 2D models and complex in vivo models. The slices require technically simple procedures and limited training, and are highly cost-effective and humane versus live animal models. Accordingly, they offer the capacity to become a standardised screening model to evaluate neuromaterials, prior to therapeutic testing in live animal models.

A Harvard startup is developing a softer device to monitor head injuries — one that doesn’t damage surrounding tissue.

Tadalafil, which has the longest half-life among PDE-5 inhibitors, does not prevent endothelial apoptosis as much as nimodipine, but it still prevents smooth muscle cell proliferation in the tunica media, restores damaged endothelial integrity, increases cerebral blood flow, and is thought to have various neuroprotective functions through the PI3K/AKT/eNOS signaling pathway. We believe that more in-depth research on tadalafil in the future will prove the therapeutic potential of this drug for DCI.

While current iBCI research predominantly focuses on device performance metrics, a critical need is emerging to rigorously assess clinical outcomes.The review found that only 17.9% of studies prospectively measured patient clinical outcomes, and these assessments were highly varied due to differing patient populations and methodologies.

Une faille critique dans la technologie eSIM a été découverte par des chercheurs. Présente sur plus de deux milliards d’appareils IoT, cette vulnérabilité permet d’installer des programmes malveillants et de voler des données. La faille a été colmatée.

Belkin abandonne sa gamme domotique WeMo, laissant sur le carreau une partie de ses clients. Dès l’année prochaine, la majorité des produits ne fonctionneront plus, sauf quelques rares exceptions compatibles HomeKit. La fin de cette gamme marque aussi les limites pénibles du marché de la maison connectée.

Although lithium is highly effective to treat bipolar disorder, the chemical has a narrow therapeutic window—too high a dose can be toxic to patients, causing kidney damage, thyroid damage, or even death, while too low a dose renders the treatment ineffective.The dose of lithium varies between individuals based on body weight, diet, and other physiological factors, and requires regular measurement of lithium levels in the blood. Currently, this is only available through standard laboratory-based blood draws, which can be time-consuming, inconvenient, and painful. This makes personalized and easily-accessible lithium monitoring an important goal in the treatment for bipolar disorder.

Emy est un dispositif connecté ludique et médical qui permet aux femmes de renforcer leur périnée à domicile, en toute autonomie et discrétion.

For the past few months, when I really needed to get something done, I put on a special pair of headphones that could read my mind. Well, kind of. The headphones are equipped with a brain-computer interface that picks up electrical signals from my brain and uses algorithms to interpret that data. When my focus starts to slip, the headphones know it, and an app tells me to take a break.

InBrain says its technology utilizes the unique properties of graphene, a material known for its strength, flexibility and conductivity, combined with machine learning software to provide highly targeted and adaptive neuroelectronic therapy. InBrain's implant is only 10 micrometers thick—thinner than a human hair—and is designed to safely decode and modulate neural signals with high accuracy. The company has set its sights on developing personalized treatments for conditions such as Parkinson’s disease, epilepsy and stroke rehabilitation. 

Synchron vient de montrer la dernière capacité de son implant Stentrode : contrôler un iPad par la pensée. Une prochaine mise à jour du système d’exploitation permettra aux appareils d’Apple d’être pilotés directement par les implants cérébraux, offrant une nouvelle forme d’indépendance pour les personnes paralysées.

A groundbreaking moment in technology and accessibility has emerged, as an individual has successfully controlled an iPad using only brain signals. There was no physical touch involved, no voice commands, no eye tracking - just the power of thought. The individual, named Mark, living with ALS, a condition that severely limits voluntary movement, has managed to use Apple's new brain‑computer interface (BCI) protocol and Synchron's implantable Stentrode device to communicate with an iPad via just his thoughts.

 Apple continue de plancher sur le contrôle cérébral de ses appareils. Au mois de mai avait circulé le témoignage de Mark Jackson, un homme lourdement handicapé aux muscles paralysés ayant tout de même pu utiliser un Vision Pro. Une nouvelle vidéo le montre maintenant utiliser un  iPad de manière avancée : il se promène sur l’écran d’accueil, lance des apps et tape du texte, le tout sans bouger ses mains ou ses yeux.

Recently, a neurotech company called Paradromics made headlines by successfully implanting its brain-computer interface (BCI) in a human for the first time. The procedure happened at the University of Michigan during a patient's routine epilepsy surgery. The device was both placed and removed in just about 20 minutes, a quick turnaround for such a complex technology. This achievement is a big deal for Paradromics, which has been working on this brain implant technology for nearly 10 years. 

Dans une interview avec Y Combinator, Elon Musk a expliqué que son implant était déjà fonctionnel chez des singes et que l'un d'eux était équipé d'un implant Blindsight depuis trois ans. Selon lui, la définition serait assez basse au début - ce qu'il avait déjà comparé par le passé aux graphismes de l'Atari - « mais à long terme, vous aurez une très haute résolution et pourrez voir des longueurs d'onde multispectrales, de sorte que vous pourrez voir un radar, l'infrarouge et l'ultraviolet, comme un superpouvoir ».